Design of Vif-Derived Peptide Inhibitors with Anti-HIV-1 Activity by Interrupting Vif-CBFβ Interaction

Yanxin Gai, Sizhu Duan, Shiqi Wang, Kaifeng Liu, Xin Yu, Chumeng Yang, Guoqing Li, Yan Zhou, Bin Yu, Jiaxin Wu, Xianghui YuViruses 2024 · DOI

TL;DR

Researchers have designed novel peptide inhibitors, VMP-63 and VMP-108, that disrupt the interaction between HIV-1's Vif protein and the host protein CBFβ. These peptides effectively reduce HIV-1 infectivity by preventing Vif from degrading the antiviral protein A3G, offering a promising new avenue for anti-HIV therapies.

What Problem Does This Paper Address?

HIV-1, the virus that causes AIDS, employs a clever strategy to overcome host defenses. One key player is the viral accessory protein Vif, which acts as a saboteur. Vif's main job is to recruit a cellular machinery called an E3 ubiquitin ligase complex to degrade APOBEC3 (A3) proteins. A3 proteins, particularly A3G, are potent antiviral factors that introduce errors into the HIV-1 genome, hindering its replication. By eliminating A3 proteins, Vif allows HIV-1 to replicate unchecked. Therefore, blocking the interaction between Vif and components of this E3 ligase complex, specifically CBFβ, presents a promising therapeutic target to restore A3's antiviral activity and inhibit HIV-1. Previous efforts have focused on other Vif interactions, leaving the Vif-CBFβ interface as a less explored but potentially crucial target.

Methods

The researchers employed a multi-pronged approach:

  • Yeast Surface Display: This technique was used to screen for Vif mutants that bind more strongly to CBFβ. By displaying mutated Vif proteins on the surface of yeast cells and then exposing them to CBFβ, they could identify Vif variants with enhanced binding affinity.
  • Peptide Design: Based on the sequences of these high-affinity Vif mutants, short peptides (9-17 amino acids) were designed. These peptides were engineered to mimic the Vif mutations that improved CBFβ binding.
  • In Vitro Assays:
    • Viral Infectivity Assay: The ability of the designed peptides to reduce HIV-1 infectivity was tested using TZM-bl cells, which are susceptible to HIV-1 infection and produce a measurable luciferase signal upon infection.
  • Western Blotting: This technique was used to assess the levels of A3G protein in cells and viral particles, demonstrating whether the peptides protected A3G from Vif-mediated degradation.
  • FRET (Förster Resonance Energy Transfer) Assay: This assay was employed to directly measure the interaction between Vif and CBFβ in living cells, confirming whether the peptides could disrupt this interaction.
  • Co-Immunoprecipitation (Co-IP): This method was used to investigate whether the peptides specifically inhibited the Vif-CBFβ interaction without affecting Vif's interaction with other components of the E3 ligase complex (CUL5, ElonginB, ElonginC).
  • Cytotoxicity Assay: Standard assays were performed to ensure the designed peptides were not toxic to cells.
  • Molecular Dynamics (MD) Simulations: These simulations were used to computationally model the binding of Vif mutants and peptides to CBFβ, providing insights into the structural basis of their interactions and binding affinities.
  • HIV-1 Replication Assays: The long-term impact of the peptides on HIV-1 replication was assessed in T lymphocyte cell lines.
  • G-to-A Mutation Analysis: This technique was used to analyze the viral genome for A3-induced mutations, confirming the restoration of A3's antiviral activity.

Datasets

Not explicitly discussed as datasets in the traditional machine learning sense. The study utilized:

  • HEK293T cells: For viral production and initial peptide testing.
  • TZM-bl cells: For viral infectivity assays.
  • CEM and CEM-SS cells: T lymphocyte cell lines used for long-term HIV-1 replication studies.
  • H9/HXB2Neo and Jurkat/HXB2Neo cells: Chronically HIV-1 infected cell lines used to confirm A3G-dependent antiviral activity.
  • HIV-1 strain NL4-3: The viral construct used in the experiments.
  • Vif mutant libraries: Generated and screened using yeast surface display.

Key Insights and Ideas

  • Targeting Vif-CBFβ is a viable strategy: The study confirms that disrupting the Vif-CBFβ interaction is a potent way to inhibit HIV-1 replication. This is significant because it expands the known targets for anti-HIV therapies beyond Vif-A3G interactions.
  • Yeast surface display is effective for identifying high-affinity binders: The method successfully identified Vif mutants with enhanced binding to CBFβ, which then served as the basis for designing effective peptide inhibitors.
  • Peptides can be designed to mimic beneficial mutations: The successful design of VMP-63 and VMP-108 demonstrates that short peptides can effectively recapitulate the binding advantages of larger protein mutants.
  • VMP-108 shows superior long-term efficacy: While both VMP-63 and VMP-108 inhibit viral infectivity and protect A3G, VMP-108 exhibits better performance in long-term replication studies in T lymphocytes, suggesting advantages in cellular uptake and stability.
  • Specificity is crucial: The study highlights that the peptides specifically target the Vif-CBFβ interaction, leaving other Vif interactions with the E3 ligase complex intact, which is important for minimizing off-target effects.

Key Results

  • Two effective peptides identified: VMP-63 and VMP-108 were identified as potent inhibitors of HIV-1 infectivity, with IC50 values of 49.4 µM and 55.1 µM, respectively.
  • Reduced viral infectivity: These peptides significantly reduced the infectivity of HIV-1 produced from A3G-positive cells.
  • Protection of A3G: VMP-63 and VMP-108 protected intracellular A3G from Vif-mediated degradation, leading to increased A3G encapsulation into progeny virions.
  • Inhibition of Vif-CBFβ interaction: FRET assays confirmed that the peptides competitively inhibited the binding of Vif to CBFβ.
  • Cellular uptake: VMP-108 demonstrated rapid cellular uptake and sustained presence within cells compared to VMP-63.
  • Long-term replication inhibition: VMP-108 effectively restricted long-term HIV-1 replication in non-permissive T lymphocytes, while VMP-63 showed less pronounced effects.
  • No significant cytotoxicity: The peptides exhibited minimal toxicity in tested cell lines.

Limitations and Future Work

  • IC50 values: The IC50 values for the peptides are in the micromolar range, which is higher than some small-molecule inhibitors. Future work should focus on improving the potency of these peptides.
  • VMP-63 vs. VMP-108: While both peptides showed promise, VMP-108 demonstrated superior performance in long-term replication assays. Further investigation into the reasons for this difference (e.g., cellular uptake, stability) is warranted.
  • Optimization of peptides: The authors suggest improving peptide activity by shortening them to their core functional regions and applying modifications such as PEGylation, lipidation, and D-amino acid substitutions.
  • In vivo studies: The current study is limited to in vitro and cell culture models. Future work should involve testing these peptides in animal models to assess their efficacy and safety in a more complex biological system.
  • Combination therapy: Exploring the potential of these peptides in combination with existing anti-HIV drugs could lead to more effective treatment strategies.

Summary updated

Abstract

One of the major functions of the accessory protein Vif of human immunodeficiency virus type 1 (HIV-1) is to induce the degradation of APOBEC3 (A3) family proteins by recruiting a Cullin5-ElonginB/C-CBFβ E3 ubiquitin ligase complex to facilitate viral replication. Therefore, the interactions between Vif and the E3 complex proteins are promising targets for the development of novel anti-HIV-1 drugs. Here, peptides are designed for the Vif-CBFβ interaction based on the sequences of Vif mutants with higher affinity for CBFβ screened by a yeast surface display platform. We identified two peptides, VMP-63 and VMP-108, that could reduce the infectivity of HIV-1 produced from A3G-positive cells with IC50 values of 49.4 μM and 55.1 μM, respectively. They protected intracellular A3G from Vif-mediated degradation in HEK293T cells, consequently increasing A3G encapsulation into the progeny virions. The peptides could rapidly enter cells after addition to HEK293T cells and competitively inhibit the binding of Vif to CBFβ. Homology modeling analysis demonstrated the binding advantages of VMP-63 and VMP-108 with CBFβ over their corresponding wild-type peptides. However, only VMP-108 effectively restricted long-term HIV-1 replication and protected A3 functions in non-permissive T lymphocytes. Our findings suggest that competitive Vif-derived peptides targeting the Vif-CBFβ interaction are promising for the development of novel therapeutic strategies for acquired immune deficiency syndrome.
BibTeX
@inproceedings{gai2024design,
  author = {Yanxin Gai and Sizhu Duan and Shiqi Wang and Kaifeng Liu and Xin Yu and Chumeng Yang and Guoqing Li and Yan Zhou and Bin Yu and Jiaxin Wu and Xianghui Yu and Xianghui Yu},
  title = {{Design of Vif-Derived Peptide Inhibitors with Anti-HIV-1 Activity by Interrupting Vif-CBFβ Interaction}},
  booktitle = {Viruses},
  year = {2024},
  doi = {10.3390/v16040490},
}
Figure